No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyLuca Prosperini, Giancarlo Di Battista, Antonio Gallo et al.|Journal of Neurology|2018Cited by 54
A real‐world study of alemtuzumab in a cohort of Italian patientsCinzia Valeria Russo, Alessio Signori, Francesco Saccà et al.|European Journal of Neurology|2021Cited by 26